Preclinical Evaluation of a Novel CAR T Therapy using Champions' DLBCL PDX Models
A Champions Case Study
Chimeric Antigen Receptor (CAR) T cell therapies have revolutionized the therapeutic management of hematological malignancies and hold great promise for solid tumors.
Diffuse Large B Cell Lymphoma (DLBCL) is a cancer of B cells and is the most common form of non-Hodgkin's Lymphoma (NHL) among adults.
In this case study, we review the preclinical evaluation of a novel CAR T therapy in our rare DLBCL PDX models.
Download the Case Study